CE / CME
In this certified on-demand webcast, experts review the latest evidence and evolving treatment strategies for HER2-positive breast cancer, including the integration of trastuzumab deruxtecan across early-stage and metastatic settings, management of brain metastases and treatment-related toxicities, and advances in HER2 testing to optimize patient care.
Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits
Pharmacists: 1.50 contact hours (0.15 CEUs)
ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Nurse Practitioners/Nurses: 1.50 Nursing contact hours
Released: June 22, 2026
Expiration: December 21, 2026
Share
Provided by Clinical Care Options, LLC dba Decera Clinical Education
Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
AstraZeneca
Daiichi Sankyo, Inc.
This activity is intended for oncologists, advanced practice providers, pharmacists, nurse practitioners, clinical nurse specialists, nurses, physician associates, and other healthcare professionals who care for patients with breast cancer.
This activity aims to improve learners’ knowledge, confidence, and competence in applying evidence-based, patient-centered care across early-stage and metastatic HER2-positive and HER2-expressing breast cancer by deepening understanding of evolving ADC evidence, optimizing treatment selection and sequencing, enhancing cross-disciplinary approaches to monitoring and supportive care, and improving the accuracy and application of HER2 testing.
Upon completion of this activity, participants should be able to:
Apply current evidence and guideline principles to select and sequence HER2-directed therapies across early-stage and metastatic breast cancer
Interpret evolving data on HER2-directed ADCs and integrate key findings into individualized treatment planning for patients with HER2-positive and HER2-expressing disease
Improve accuracy in ordering, interpreting, and communicating HER2 IHC and ISH results, including differentiation of HER2-positive, HER2-low, and HER2-ultralow categories, and determine when repeat testing is clinically appropriate
Identify early indicators of treatment-related events associated with HER2-directed therapies and coordinate multidisciplinary approaches to monitoring, evaluation, and supportive care
Incorporate real-world considerations such as CNS involvement, comorbidities, treatment tolerability, and patient preferences into evidence-based therapeutic decision-making
Recognize appropriate candidates for clinical trials and employ patient-centered communication strategies to support equitable access to emerging therapies
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary AuthorIan Krop, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech, Puma, Seagen.
Adrienne G. Waks, MD: consultant/advisor/speaker: AstraZeneca, Genentech, Jazz, Johnson & Johnson, Pfizer; research (support to institution): Genentech, Gilead, Merck, TerSera.
The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below:
Kristi K. Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Stemline.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 22, 2026, through December 21, 2026:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.
Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.5 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-26-357-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 21, 2026. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification ![]()
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).
IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.